Cancer vaccines: the next immunotherapy frontier
MJ Lin, J Svensson-Arvelund, GS Lubitz, A Marabelle… - Nature cancer, 2022 - nature.com
After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate …
glioblastoma remain poor, and new treatments are needed. Objective To investigate …
Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Challenges in glioblastoma research: focus on the tumor microenvironment
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive
molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has …
molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has …
[HTML][HTML] EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
M Weller, M van den Bent, M Preusser… - Nature reviews Clinical …, 2021 - nature.com
In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10
Despite recent advances in cancer immunotherapy, certain tumor types, such as
Glioblastomas, are highly resistant due to their tumor microenvironment disabling the anti …
Glioblastomas, are highly resistant due to their tumor microenvironment disabling the anti …
[HTML][HTML] A vaccine targeting mutant IDH1 in newly diagnosed glioma
Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …
cause of morbidity and mortality. In recent years there have been important advances in …